Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Arcellx Inc (ACLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ACLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $113.07
1 Year Target Price $113.07
| 12 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 41.49% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.99B USD | Price to earnings Ratio - | 1Y Target Price 113.07 |
Price to earnings Ratio - | 1Y Target Price 113.07 | ||
Volume (30-day avg) 18 | Beta 0.28 | 52 Weeks Range 47.86 - 107.37 | Updated Date 08/15/2025 |
52 Weeks Range 47.86 - 107.37 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.41 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -1.02 | Actual -0.94 |
Profitability
Profit Margin - | Operating Margin (TTM) -777.42% |
Management Effectiveness
Return on Assets (TTM) -19.8% | Return on Equity (TTM) -42.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3584687416 | Price to Sales(TTM) 69.94 |
Enterprise Value 3584687416 | Price to Sales(TTM) 69.94 | ||
Enterprise Value to Revenue 62.91 | Enterprise Value to EBITDA -6.52 | Shares Outstanding 55458900 | Shares Floating 32713548 |
Shares Outstanding 55458900 | Shares Floating 32713548 | ||
Percent Insiders 14.41 | Percent Institutions 102.69 |
Upturn AI SWOT
Arcellx Inc
Company Overview
History and Background
Arcellx, Inc. is a clinical-stage biotechnology company founded in 2015. It focuses on developing cell therapies for cancer and other diseases, using its ARC-SparX platform. The company went public in 2022.
Core Business Areas
- Cell Therapy Development: Arcellx develops and commercializes cell therapies based on its proprietary ARC-SparX technology platform, targeting cancer treatment.
Leadership and Structure
Arcellx is led by a team of experienced biotechnology executives. The company operates with a focus on research and development, clinical trials, and commercialization of its cell therapy products.
Top Products and Market Share
Key Offerings
- Cart-ddBCMA (Anitocabtagene autoleucel): Cart-ddBCMA is Arcellx's lead product candidate, a BCMA-targeting CAR-T therapy for relapsed or refractory multiple myeloma. It is currently in Phase 2 trials. Market share data is not yet publicly available as the product is not commercialized. Competitors include Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY) with their CAR-T therapies.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, with increasing investment and regulatory approvals. CAR-T therapies are becoming a key treatment option for certain cancers.
Positioning
Arcellx is positioned as an innovator in cell therapy, using its ARC-SparX platform to create differentiated CAR-T products.
Total Addressable Market (TAM)
The TAM for multiple myeloma and other blood cancers is substantial, estimated to be several billion dollars annually. Arcellx is positioned to capture a portion of this market with its CAR-T therapy.
Upturn SWOT Analysis
Strengths
- Proprietary ARC-SparX technology platform
- Promising clinical trial results for Cart-ddBCMA
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical stage company with no currently approved products
- Dependence on successful clinical trial outcomes
- High cost of cell therapy manufacturing
- Limited commercialization experience
Opportunities
- Potential for accelerated regulatory approval
- Expansion of ARC-SparX platform to other cancer targets
- Partnerships with larger pharmaceutical companies
- Increasing adoption of cell therapies in oncology
Threats
- Competition from established CAR-T therapies
- Regulatory hurdles and delays
- Manufacturing challenges and scalability issues
- Adverse events or safety concerns in clinical trials
Competitors and Market Share
Key Competitors
- LEGN
- BMY
- GILD
- BLUE
Competitive Landscape
Arcellx's ARC-SparX platform offers potential advantages over existing CAR-T therapies, but it faces intense competition from established players with approved products.
Growth Trajectory and Initiatives
Historical Growth: Arcellx's historical growth has been driven by the advancement of its ARC-SparX platform and the progress of Cart-ddBCMA through clinical trials.
Future Projections: Future growth will depend on the successful commercialization of Cart-ddBCMA and other pipeline products. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 2 trial of Cart-ddBCMA and expansion of platform technologies.
Summary
Arcellx is a clinical-stage biotechnology company with a promising cell therapy platform. The success of Cart-ddBCMA in clinical trials is critical for future growth. Competition in the CAR-T space is intense and therefore Arcellx must demonstrate superiority of its platform. The company's financial health will depend on its ability to raise capital and eventually generate revenue from commercialized products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcellx's Investor Relations website
- SEC filings
- Analyst reports
- Clinical trial publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcellx Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2022-02-04 | Chairman of the Board, CEO & President Mr. Rami Elghandour | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.arcellx.com |
Full time employees 163 | Website https://www.arcellx.com | ||
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.